Our aim was to investigate the role of switching from emtricitabine/tenofovir alafenamide (FTC/TAF) based reg imen to a dolutegravir (DTG) containing two-drug regimen (2DR) vs continuing FTC/TAF on metabolic parameters
P35 Previous COBI-including regimen is the major determinant of lipid profile modification in a cohort of PWH on stable TAF treatment switching to dual treatment
Pellicano', G;
2025-01-01
Abstract
Our aim was to investigate the role of switching from emtricitabine/tenofovir alafenamide (FTC/TAF) based reg imen to a dolutegravir (DTG) containing two-drug regimen (2DR) vs continuing FTC/TAF on metabolic parametersFile in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
